未登录Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Michel, Christian; Burchert, Andreas; Hochhaus, Andreas; Saussele, Susanne; Neubauer, Andreas; Lauseker, Michael; Krause, Stefan W.; Kolb, Hans-Jochem; Hossfeld, Dieter Kurt; Nerl, Christoph; Baerlocher, Gabriela M.; Heim, Dominik; Bruemmendorf, Tim H.; Fabarius, Alice; Haferlach, Claudia; Schlegelberger, Brigitte; Balleisen, Leopold; Goebeler, Maria-Elisabeth; Haenel, Mathias; Ho, Anthony; Dengler, Jolanta; Falge, Christiane; Moehle, Robert; Kremers, Stephan; Kneba, Michael; Stegelmann, Frank; Koehne, Claus-Henning; Lindemann, Hans-Walter; Waller, Cornelius F.; Spiekermann, Karsten; Berdel, Wolfgang E.; Mueller, Lothar; Edinger, Matthias; Mayer, Jiri; Beelen, Dietrich W.; Bentz, Martin; Link, Hartmut; Hertenstein, Bernd; Fuchs, Roland; Wernli, Martin; Schlegel, Frank; Schlag, Rudolf; de Wit, Maike; Truemper, Lorenz; Hebart, Holger; Hahn, Markus; Thomalla, Joerg; Scheid, Christof; Schafhausen, Philippe; Verbeek, Walter; Eckart, Michael J.; Gassmann, Winfried; Schenk, Michael; Brossart, Peter; Wuendisch, Thomas; Geer, Thomas; Bildat, Stephan; Schaefer, Erhardt; Hasford, Joerg; Hehlmann, Ruediger; Pfirrmann, Markus .png)
分享.png)
收藏分享 收藏 分享 收藏 The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)Buske, C.; Hoster, E.; Dreyling, M.; Eimermacher, H.; Wandt, H.; Metzner, B.; Fuchs, R.; Bittenbring, J.; Woermann, B.; Hohloch, K.; Hess, G.; Ludwig, W-D; Schimke, J.; Schmitz, S.; Kneba, M.; Reiser, M.; Graeven, U.; Klapper, W.; Unterhalt, M.; Hiddemann, W. 分享 收藏 Equitoxicity of bolus and infusional etoposide:: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)Zwick, Carsten; Birkmann, Josef; Peter, Norma; Bodenstein, Heinrich; Fuchs, Roland; Haenel, Mathias; Reiser, Marcel; Hensel, Manfred; Clemens, Michael; Zeynalova, Samira; Ziepert, Marita; Pfreundschuh, Michael 分享 收藏 The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1Walz, C; Chase, A; Schoch, C; Weisser, A; Schlegel, F; Hochhaus, A; Fuchs, R; Schmitt-Gräff, A; Hehlmann, R; Cross, NCP; Reiter, A 分享 收藏 Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia:: results of a prospective multicenter phase II trialKern, W; Braess, J; Grote-Metke, A; Kuse, H; Fuchs, R; Hossfeld, DK; Reichle, A; Wörmann, B; Büchner, T; Hiddemann, W 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF HEMATOLOGY.png)
